Stephen J. Ubl

America’s biopharma leadership fuels jobs, cures and economic growth. It matters. Harmful policies put us at risk of losing this competitive edge while China races to overtake us by investing heavily in biopharmaceutical R&D. Policymakers must continue to invest in smart policies to keep America in the lead. americacures.com

Lori is right: MFN won’t lower what U.S. patients pay, and it risks delaying access to medicines for patients who can’t afford to wait.

Leadership in medical innovation is not automatic. Smart policies will deliver more cures, more jobs and lower costs to Americans. That is the path forward. Learn more: phrma.org/blog/americans…

Large hospital conglomerates are driving 40% of the growth in health care spending, often by abusing programs like 340B. Buying medicines for pennies and marking them up 1,000% is not a solution for patients. It’s a barrier. We must fix 340B. Learn more: phrma.org/policy-issues/…

Congratulations to this week’s #WorkingforCures champion from @GileadSciences, Woodie Zachry. Woodie is a fantastic partner to the Government Affairs team who approaches issues from a policy and economic lens and has helped create research that supports Gilead’s policy objectives. Congratulations, Woodie!

Biopharmaceutical innovation strengthens both health and economic security. The U.S. has 1,500+ manufacturing facilities across 48 states supporting millions of jobs. Smart policy choices will help ensure the next generation of cures is discovered here. Read more of my conversation with @washingtonpost: washingtonpost.com/creativegroup/…

.@UCBUSA's new biologics facility in Georgia reflects a long-term commitment to patients, innovation and growth in the U.S. It will strengthen manufacturing, support the pipeline and create high-quality jobs while bringing medicines closer to patients. ucb.com/newsroom/press…

A bloated health care system does not serve patients. Administrative layers and middlemen drive up costs without improving care. Real reform means real accountability across the supply chain.

It takes 10+ years and $2–3B to develop a new medicine. Only 10% succeed. AI can help us dramatically improve every step — from molecule design to clinical trials. The countries that lead in AI-integrated biopharma will lead in cures. America must lead.

Meet Oscar Merino, our #WorkingforCures champion from @Genmab. Oscar helps educate lawmakers and push for change to address broader access issues, drive representation in clinical trials and build understanding around the need for new innovations. This is amazing work, Oscar.

In my conversation with the @washingtonpost, I discussed why America leads in biopharmaceutical innovation. Our ecosystem turns cutting-edge science into medicines for patients and supports millions of jobs. Protecting the policies that support innovation matters. Read the full Q&A here: washingtonpost.com/creativegroup/…

Congratulations to our first champion from @genentech #WorkingforCures, Colleen Dodson. Colleen raises awareness in underserved communities, engages stakeholders in dialogue about #biopharma innovation and champions programs that remove barriers to care and expand patient education. Congratulations, Colleen!

America’s leadership in medical discovery was made possible by a pro-innovation policy environment. But progress is not promised—it falls on our legislators to ensure that we maintain our competitive edge and position as the world’s leader in innovation. Learn more below.

Across the country, biopharmaceutical companies are investing in research, manufacturing and jobs. These investments strengthen communities, grow our economy and reinforce America’s leadership in innovation.

.@CSL broke ground on a $1.5B expansion of its manufacturing facility in Kankakee, Illinois. Building on their $3 billion investment since 2018, the project will expand production of plasma-derived therapies for people living with rare and serious diseases and create 300 new jobs.

Cell and gene therapies address the root causes of disease and offer durable, curative, outcomes with a single dose. Coverage and payment structures must evolve to ensure patients can access these life-changing medicines. Read more: phrma.org/futureofmedici…

Innovation doesn’t happen in a vacuum. During this year’s PhRMA Forum, industry experts convened to discuss what it takes to keep the U.S. leading in biomedical breakthroughs. AmericaCures.com

I am proud to announce this week’s #WorkingforCures champion, Phung Osborn from @bmsnews. Phung is a leading voice in expanding patient access to transformative CAR-T therapies and works closely with treatment centers, payers and patient organizations to improve understanding of cell therapy access barriers. Thank you, Phung, and congratulations.

American leadership in medicine is built through investment at home. Novartis plans to build a new radioligand therapy facility in Texas, expanding U.S. manufacturing capacity, strengthening supply chains, and creating jobs while supporting next-generation cancer treatments. That’s how we lead. More: urlisolation.com/browser?clickI…

America’s biopharma leadership fuels jobs, cures and economic growth. Most Favored Nation would import foreign price setting policies and weaken our competitive edge. We should strengthen American innovation, not undermine it.

America’s biopharma leadership fuels jobs, cures and economic growth. It matters. @JNJInnovation’s more than $1 billion investment in next generation cell therapy manufacturing in Pennsylvania will create thousands of jobs and expand U.S. capacity for transformational medicines. We need policies that keep this momentum going and protect our competitive edge. jnj.com/media-center/p…